25 XP   0   0   10

AC Immune Ltd
Buy, Hold or Sell?

Let's analyse AC Immune Ltd together

PenkeI guess you are interested in AC Immune Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AC Immune Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about AC Immune Ltd

I send you an email if I find something interesting about AC Immune Ltd.

Quick analysis of AC Immune Ltd (30 sec.)










What can you expect buying and holding a share of AC Immune Ltd? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.8%

What is your share worth?

Current worth
$1.44
Expected worth in 1 year
$0.70
How sure are you?
30.6%

+ What do you gain per year?

Total Gains per Share
$-0.74
Return On Investment
-19.2%

For what price can you sell your share?

Current Price per Share
$3.85
Expected price per share
$2.3 - $5.14
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of AC Immune Ltd (5 min.)




Live pricePrice per Share (EOD)

$3.85

Intrinsic Value Per Share

$-4.78 - $-5.41

Total Value Per Share

$-3.34 - $-3.97

2. Growth of AC Immune Ltd (5 min.)




Is AC Immune Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$142.3m$237.6m-$71.4m-42.9%

How much money is AC Immune Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$19.3m-$20.7m$1.4m7.4%
Net Profit Margin-468,725.0%-85.9%--

How much money comes from the company's main activities?

3. Financial Health of AC Immune Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#330 / 1045

Most Revenue
#715 / 1045

Most Profit
#732 / 1045

Most Efficient
#1040 / 1045
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of AC Immune Ltd? (5 min.)

Welcome investor! AC Immune Ltd's management wants to use your money to grow the business. In return you get a share of AC Immune Ltd.

What can you expect buying and holding a share of AC Immune Ltd?

First you should know what it really means to hold a share of AC Immune Ltd. And how you can make/lose money.

Speculation

The Price per Share of AC Immune Ltd is $3.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of AC Immune Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in AC Immune Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.44. Based on the TTM, the Book Value Change Per Share is $-0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of AC Immune Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.17-4.5%-0.19-5.0%-0.21-5.5%-0.13-3.3%-0.08-2.0%
Usd Book Value Change Per Share-0.16-4.1%-0.18-4.8%0.030.8%-0.04-1.0%0.041.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.16-4.1%-0.18-4.8%0.030.8%-0.04-1.0%0.041.0%
Usd Price Per Share2.85-2.55-3.93-5.27-5.71-
Price to Earnings Ratio-4.10--3.33--4.70--6.13--43.42-
Price-to-Total Gains Ratio-18.19--14.57--15.19--26.24--33.03-
Price to Book Ratio1.98-1.55-1.62-2.19-3.15-
Price-to-Total Gains Ratio-18.19--14.57--15.19--26.24--33.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.85
Number of shares259
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.18-0.04
Usd Total Gains Per Share-0.18-0.04
Gains per Quarter (259 shares)-47.81-9.85
Gains per Year (259 shares)-191.26-39.39
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-191-2010-39-49
20-383-3920-79-88
30-574-5830-118-127
40-765-7740-158-166
50-956-9650-197-205
60-1148-11560-236-244
70-1339-13470-276-283
80-1530-15380-315-322
90-1721-17290-355-361
100-1913-19200-394-400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%8.028.00.022.2%8.028.00.022.2%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%11.023.02.030.6%11.023.02.030.6%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.035.02.8%1.00.035.02.8%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%4.016.00.020.0%11.023.02.030.6%11.023.02.030.6%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of AC Immune Ltd

About AC Immune Ltd

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Fundamental data was last updated by Penke on 2024-02-27 15:54:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of AC Immune Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit AC Immune Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AC Immune Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-468,725.0%+468,725.0%
TTM-468,725.0%YOY-85.9%-468,639.1%
TTM-468,725.0%5Y-94,207.5%-374,517.5%
5Y-94,207.5%10Y-52,612.8%-41,594.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--188.7%+188.7%
TTM-468,725.0%-211.4%-468,513.6%
YOY-85.9%-286.5%+200.6%
5Y-94,207.5%-469.5%-93,738.0%
10Y-52,612.8%-609.8%-52,003.0%
1.1.2. Return on Assets

Shows how efficient AC Immune Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • -10.6% Return on Assets means that AC Immune Ltd generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AC Immune Ltd:

  • The MRQ is -10.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM-10.5%-0.1%
TTM-10.5%YOY-7.9%-2.5%
TTM-10.5%5Y-5.8%-4.7%
5Y-5.8%10Y-2.3%-3.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-12.7%+2.1%
TTM-10.5%-12.4%+1.9%
YOY-7.9%-11.4%+3.5%
5Y-5.8%-13.9%+8.1%
10Y-2.3%-15.6%+13.3%
1.1.3. Return on Equity

Shows how efficient AC Immune Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • -12.1% Return on Equity means AC Immune Ltd generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AC Immune Ltd:

  • The MRQ is -12.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.1%TTM-11.7%-0.4%
TTM-11.7%YOY-8.7%-3.0%
TTM-11.7%5Y-6.2%-5.5%
5Y-6.2%10Y-2.1%-4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.1%-16.3%+4.2%
TTM-11.7%-16.2%+4.5%
YOY-8.7%-14.7%+6.0%
5Y-6.2%-19.1%+12.9%
10Y-2.1%-20.0%+17.9%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of AC Immune Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient AC Immune Ltd is operating .

  • Measures how much profit AC Immune Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AC Immune Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-467,425.0%+467,425.0%
TTM-467,425.0%YOY-85.6%-467,339.4%
TTM-467,425.0%5Y-93,934.2%-373,490.8%
5Y-93,934.2%10Y-52,455.0%-41,479.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--302.9%+302.9%
TTM-467,425.0%-220.2%-467,204.8%
YOY-85.6%-288.3%+202.7%
5Y-93,934.2%-461.8%-93,472.4%
10Y-52,455.0%-610.0%-51,845.0%
1.2.2. Operating Ratio

Measures how efficient AC Immune Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AC Immune Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8,458.500-8,458.500
TTM8,458.500YOY1.106+8,457.394
TTM8,458.5005Y1,698.371+6,760.129
5Y1,698.37110Y949.727+748.644
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.963-2.963
TTM8,458.5003.251+8,455.249
YOY1.1063.828-2.722
5Y1,698.3715.978+1,692.393
10Y949.7277.505+942.222
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of AC Immune Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if AC Immune Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.36 means the company has $7.36 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AC Immune Ltd:

  • The MRQ is 7.359. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.448. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.359TTM9.448-2.088
TTM9.448YOY12.280-2.832
TTM9.4485Y14.732-5.284
5Y14.73210Y13.698+1.034
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3594.010+3.349
TTM9.4484.478+4.970
YOY12.2805.577+6.703
5Y14.7326.222+8.510
10Y13.6986.568+7.130
1.3.2. Quick Ratio

Measures if AC Immune Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 10.99 means the company can pay off $10.99 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AC Immune Ltd:

  • The MRQ is 10.986. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.295. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.986TTM14.295-3.309
TTM14.295YOY19.613-5.318
TTM14.2955Y20.300-6.005
5Y20.30010Y16.668+3.632
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.9863.566+7.420
TTM14.2954.169+10.126
YOY19.6135.472+14.141
5Y20.3006.097+14.203
10Y16.6686.383+10.285
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of AC Immune Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of AC Immune Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare AC Immune Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that AC Immune Ltd assets are financed with 12.1% credit (debt) and the remaining percentage (100% - 12.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AC Immune Ltd:

  • The MRQ is 0.121. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.104. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.121TTM0.104+0.017
TTM0.104YOY0.086+0.018
TTM0.1045Y0.099+0.005
5Y0.09910Y0.112-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1210.332-0.211
TTM0.1040.329-0.225
YOY0.0860.262-0.176
5Y0.0990.371-0.272
10Y0.1120.380-0.268
1.4.2. Debt to Equity Ratio

Measures if AC Immune Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.8% means that company has $0.14 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AC Immune Ltd:

  • The MRQ is 0.138. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.116. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.138TTM0.116+0.021
TTM0.116YOY0.094+0.022
TTM0.1165Y0.112+0.005
5Y0.11210Y0.130-0.018
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1380.375-0.237
TTM0.1160.396-0.280
YOY0.0940.317-0.223
5Y0.1120.425-0.313
10Y0.1300.477-0.347
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of AC Immune Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings AC Immune Ltd generates.

  • Above 15 is considered overpriced but always compare AC Immune Ltd to the Biotechnology industry mean.
  • A PE ratio of -4.10 means the investor is paying $-4.10 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AC Immune Ltd:

  • The EOD is -5.542. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.103. Based on the earnings, the company is expensive. -2
  • The TTM is -3.333. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.542MRQ-4.103-1.440
MRQ-4.103TTM-3.333-0.770
TTM-3.333YOY-4.700+1.367
TTM-3.3335Y-6.134+2.801
5Y-6.13410Y-43.425+37.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.542-2.636-2.906
MRQ-4.103-2.324-1.779
TTM-3.333-2.801-0.532
YOY-4.700-4.414-0.286
5Y-6.134-6.185+0.051
10Y-43.425-6.292-37.133
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of AC Immune Ltd:

  • The EOD is -6.180. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.575. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.659. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.180MRQ-4.575-1.605
MRQ-4.575TTM-3.659-0.915
TTM-3.659YOY-4.618+0.959
TTM-3.6595Y-6.516+2.856
5Y-6.51610Y-5.760-0.756
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.180-3.656-2.524
MRQ-4.575-2.911-1.664
TTM-3.659-3.541-0.118
YOY-4.618-6.023+1.405
5Y-6.516-8.362+1.846
10Y-5.760-8.792+3.032
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of AC Immune Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.98 means the investor is paying $1.98 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AC Immune Ltd:

  • The EOD is 2.671. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.978. Based on the equity, the company is underpriced. +1
  • The TTM is 1.553. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.671MRQ1.978+0.694
MRQ1.978TTM1.553+0.424
TTM1.553YOY1.623-0.069
TTM1.5535Y2.189-0.636
5Y2.18910Y3.154-0.965
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6712.155+0.516
MRQ1.9781.883+0.095
TTM1.5532.134-0.581
YOY1.6233.019-1.396
5Y2.1893.616-1.427
10Y3.1544.009-0.855
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AC Immune Ltd.

3.1. Institutions holding AC Immune Ltd

Institutions are holding 30.344% of the shares of AC Immune Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Bvf Inc7.51850.5709742837900
2023-09-30Avidity Partners Management LP3.00580.34092969800665222.2913
2023-09-30Morgan Stanley - Brokerage Accounts1.76280.00051741677-16364-0.9308
2023-09-30Junked Platinum Investment Management Ltd1.33850.147132246200
2023-09-30Wells Fargo & Co1.160.001114608663280.5552
2023-12-31Renaissance Technologies Corp0.42260.0032417579-7600-1.7875
2023-09-30Deutsche Bank AG0.25640.000525337500
2023-12-31Eversept Partners, LLC0.12610.054712458900
2023-12-31Assenagon Asset Management SA0.11280.001511141800
2023-12-31Handelsbanken Fonder AB0.10230.002510106400
2023-09-30Banque Cantonale Vaudoise0.08170.01158070100
2023-09-30Susquehanna International Group, LLP0.0724071487-3885-5.1544
2023-12-31Dimensional Fund Advisors, Inc.0.06050.00015975200
2023-09-30UBS Group AG0.04350429741000.2332
2023-09-30Geode Capital Management, LLC0.0414040914379610.2268
2023-09-30Tower Research Capital LLC0.01990.001819638192484935.3846
2023-09-30COHEN LAWRENCE B0.0130.02471285000
2023-12-31Compagnie Lombard, Odier SCA0.01010.00091000000
2023-09-30Group One Trading, LP0.00530.00015255224374.4688
2023-09-30BlackRock Inc0.00410401800
Total 16.15771.161815964018+70388+0.4%

3.2. Funds holding AC Immune Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31BlackRock Health Sciences Opps Inv A1.09650.0419108334000
2024-01-31BlackRock Health Sciences Term Trust0.76150.128275239000
2024-01-31Handelsbanken Europa Småbolag (A1 SEK)0.54760.7624541064-10000-1.8147
2024-01-31iShares Biotechnology ETF0.42640.0185421320-386-0.0915
2023-12-31DWS ESG Biotech LC0.25650.32325338000
2023-12-31Monega ARIAD Innovation R0.21210.672820956800
2024-01-31Pacific Select Health Sciences I0.05380.04145315000
2024-01-31iShares Nasdaq US Biotech ETF USD Acc0.04210.02754164000
2023-12-31Fidelity Nasdaq Composite Index0.04140.00144091400
2023-12-31Top Class Healthcare FI0.02830.98462800000
2023-12-31Fidelity Select Biotechnology0.02750.00327202272020
2023-12-31DFA US Vector Equity I0.0160.00171582100
2023-12-31Dimensional Global Trgtd Value USD Acc0.01410.00141395900
2023-12-31DFA US Micro Cap I0.01070.00071053000
2024-01-31LUX IM Global Medtech HX0.00970.0148961700
2023-12-31DFA US Core Equity 2 I0.00830.0001819700
2024-01-31ProShares Ultra Nasdaq Biotechnology0.00640.0214628700
2023-12-31DFA US Core Equity 1 I0.00490.0001479200
2023-12-31Platinum World Portfolios-Intl D USD Acc0.00470.0529459700
2024-01-31Invesco Nasdaq Biotechnology ETF0.0020.0276202100
Total 3.57053.12543527789+16816+0.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of AC Immune Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.157-0.185+18%0.031-605%-0.038-76%0.040-491%
Book Value Per Share--1.4411.683-14%2.405-40%2.422-41%1.827-21%
Current Ratio--7.3599.448-22%12.280-40%14.732-50%13.698-46%
Debt To Asset Ratio--0.1210.104+16%0.086+41%0.099+22%0.112+8%
Debt To Equity Ratio--0.1380.116+18%0.094+46%0.112+23%0.130+6%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---0.174-0.194+12%-0.210+21%-0.129-26%-0.077-56%
Free Cash Flow Per Share---0.156-0.179+15%-0.218+40%-0.119-23%-0.078-50%
Free Cash Flow To Equity Per Share---0.151-0.173+15%-0.139-8%-0.068-55%0.022-772%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---5.407--------
Intrinsic Value_10Y_min---4.778--------
Intrinsic Value_1Y_max---0.760--------
Intrinsic Value_1Y_min---0.747--------
Intrinsic Value_3Y_max---2.118--------
Intrinsic Value_3Y_min---2.025--------
Intrinsic Value_5Y_max---3.275--------
Intrinsic Value_5Y_min---3.054--------
Market Cap380385390.000+26%281583990.000251573064.750+12%388289502.000-27%520510475.550-46%564279495.750-50%
Net Profit Margin----4687.2500%-0.8590%-942.0750%-526.1280%
Operating Margin----4674.2500%-0.8560%-939.3420%-524.5500%
Operating Ratio---8458.500-100%1.106-100%1698.371-100%949.727-100%
Pb Ratio2.671+26%1.9781.553+27%1.623+22%2.189-10%3.154-37%
Pe Ratio-5.542-35%-4.103-3.333-19%-4.700+15%-6.134+50%-43.425+958%
Price Per Share3.850+26%2.8502.546+12%3.930-27%5.268-46%5.711-50%
Price To Free Cash Flow Ratio-6.180-35%-4.575-3.659-20%-4.618+1%-6.516+42%-5.760+26%
Price To Total Gains Ratio-24.568-35%-18.187-14.569-20%-15.192-16%-26.243+44%-33.027+82%
Quick Ratio--10.98614.295-23%19.613-44%20.300-46%16.668-34%
Return On Assets---0.106-0.105-1%-0.079-25%-0.058-46%-0.023-78%
Return On Equity---0.121-0.117-3%-0.087-28%-0.062-49%-0.021-82%
Total Gains Per Share---0.157-0.185+18%0.031-604%-0.038-76%0.040-491%
Usd Book Value--142389878.400166259196.450-14%237660926.400-40%239344089.795-41%180511170.875-21%
Usd Book Value Change Per Share---0.157-0.185+18%0.031-605%-0.038-76%0.040-491%
Usd Book Value Per Share--1.4411.683-14%2.405-40%2.422-41%1.827-21%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.174-0.194+12%-0.210+21%-0.129-26%-0.077-56%
Usd Free Cash Flow---15387498.000-17648032.500+15%-21503121.975+40%-11776308.300-23%-7747917.475-50%
Usd Free Cash Flow Per Share---0.156-0.179+15%-0.218+40%-0.119-23%-0.078-50%
Usd Free Cash Flow To Equity Per Share---0.151-0.173+15%-0.139-8%-0.068-55%0.022-772%
Usd Market Cap380385390.000+26%281583990.000251573064.750+12%388289502.000-27%520510475.550-46%564279495.750-50%
Usd Price Per Share3.850+26%2.8502.546+12%3.930-27%5.268-46%5.711-50%
Usd Profit---17158533.300-19330119.450+13%-20759241.825+21%-12713268.690-26%-8285132.775-52%
Usd Revenue---283.275-100%1114403.850-100%7485258.600-100%7898305.025-100%
Usd Total Gains Per Share---0.157-0.185+18%0.031-604%-0.038-76%0.040-491%
 EOD+5 -3MRQTTM+18 -13YOY+8 -255Y+4 -2910Y+4 -29

4.2. Fundamental Score

Let's check the fundamental score of AC Immune Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.542
Price to Book Ratio (EOD)Between0-12.671
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.986
Current Ratio (MRQ)Greater than17.359
Debt to Asset Ratio (MRQ)Less than10.121
Debt to Equity Ratio (MRQ)Less than10.138
Return on Equity (MRQ)Greater than0.15-0.121
Return on Assets (MRQ)Greater than0.05-0.106
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of AC Immune Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.036
Ma 20Greater thanMa 503.189
Ma 50Greater thanMa 1003.803
Ma 100Greater thanMa 2003.433
OpenGreater thanClose3.700
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CHF. All numbers in thousands.

Summary
Total Assets142,986
Total Liabilities17,322
Total Stockholder Equity125,664
 As reported
Total Liabilities 17,322
Total Stockholder Equity+ 125,664
Total Assets = 142,986

Assets

Total Assets142,986
Total Current Assets86,179
Long-term Assets56,807
Total Current Assets
Cash And Cash Equivalents 31,927
Short-term Investments 48,000
Net Receivables 718
Inventory -406
Other Current Assets 5,940
Total Current Assets  (as reported)86,179
Total Current Assets  (calculated)86,179
+/-0
Long-term Assets
Property Plant Equipment 6,030
Long Term Investments 361
Intangible Assets 50,416
Long-term Assets  (as reported)56,807
Long-term Assets  (calculated)56,807
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,710
Long-term Liabilities5,612
Total Stockholder Equity125,664
Total Current Liabilities
Short-term Debt 555
Accounts payable 1,479
Other Current Liabilities 9,338
Total Current Liabilities  (as reported)11,710
Total Current Liabilities  (calculated)11,372
+/- 338
Long-term Liabilities
Capital Lease Obligations 2,393
Long-term Liabilities  (as reported)5,612
Long-term Liabilities  (calculated)2,393
+/- 3,219
Total Stockholder Equity
Common Stock1,802
Retained Earnings -310,488
Accumulated Other Comprehensive Income 5
Other Stockholders Equity 434,345
Total Stockholder Equity (as reported)125,664
Total Stockholder Equity (calculated)125,664
+/-0
Other
Capital Stock1,802
Cash and Short Term Investments 79,927
Common Stock Shares Outstanding 84,716
Current Deferred Revenue338
Liabilities and Stockholders Equity 142,986
Net Debt -29,534
Net Invested Capital 125,664
Net Working Capital 74,469
Property Plant and Equipment Gross 16,609
Short Long Term Debt Total 2,393



Balance Sheet

Currency in CHF. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
30,497
0
0
55,100
79,931
73,545
103,282
160,683
156,100
144,599
131,288
125,441
132,013
120,014
112,556
208,724
196,556
312,892
296,222
315,349
299,250
288,232
273,258
256,610
238,740
227,959
211,090
203,396
261,443
235,519
216,786
205,557
185,938
169,150
156,228
142,986
142,986156,228169,150185,938205,557216,786235,519261,443203,396211,090227,959238,740256,610273,258288,232299,250315,349296,222312,892196,556208,724112,556120,014132,013125,441131,288144,599156,100160,683103,28273,54579,93155,1000030,497
   > Total Current Assets 
29,667
0
0
54,500
79,346
72,813
102,529
159,683
154,894
142,389
128,759
122,781
129,534
116,450
108,881
205,197
192,928
306,936
290,346
309,450
292,774
282,020
267,144
250,589
231,767
220,489
202,802
195,376
202,634
177,058
158,380
147,602
128,094
111,688
99,152
86,179
86,17999,152111,688128,094147,602158,380177,058202,634195,376202,802220,489231,767250,589267,144282,020292,774309,450290,346306,936192,928205,197108,881116,450129,534122,781128,759142,389154,894159,683102,52972,81379,34654,5000029,667
       Cash And Cash Equivalents 
3,328
0
0
53,700
76,522
67,860
82,377
157,592
152,210
138,084
124,180
117,210
124,377
109,669
102,664
199,122
156,462
222,138
205,735
212,457
193,587
182,860
177,464
176,567
160,893
151,092
104,135
93,584
82,216
57,835
63,147
44,503
31,586
57,434
40,007
31,927
31,92740,00757,43431,58644,50363,14757,83582,21693,584104,135151,092160,893176,567177,464182,860193,587212,457205,735222,138156,462199,122102,664109,669124,377117,210124,180138,084152,210157,59282,37767,86076,52253,700003,328
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,000
80,000
80,000
90,000
95,000
95,000
85,000
70,000
65,000
65,000
95,000
95,000
116,000
116,000
91,000
96,000
91,000
48,000
53,000
48,000
48,00053,00048,00091,00096,00091,000116,000116,00095,00095,00065,00065,00070,00085,00095,00095,00090,00080,00080,00030,0000000000000000000
       Net Receivables 
25,980
0
0
200
316
1,762
15,880
1,259
1,406
2,022
2,615
3,587
3,717
4,243
3,044
3,390
4,102
1,798
1,694
3,996
1,399
741
991
1,258
1,920
1,067
941
433
1,403
418
768
4,211
800
816
978
718
7189788168004,2117684181,4034339411,0671,9201,2589917411,3993,9961,6941,7984,1023,3903,0444,2433,7173,5872,6152,0221,4061,25915,8801,7623162000025,980
       Other Current Assets 
375
0
0
600
2,508
3,191
4,272
832
1,278
2,283
1,964
1,984
1,440
2,538
3,173
2,685
2,364
3,000
2,917
2,997
2,788
3,419
3,689
2,764
3,954
3,330
2,726
6,359
3,015
2,805
3,465
2,888
4,708
6,036
5,470
5,940
5,9405,4706,0364,7082,8883,4652,8053,0156,3592,7263,3303,9542,7643,6893,4192,7882,9972,9173,0002,3642,6853,1732,5381,4401,9841,9642,2831,2788324,2723,1912,50860000375
   > Long-term Assets 
0
0
0
600
585
732
753
1,000
1,206
2,210
2,529
2,660
2,479
3,564
3,675
3,527
3,628
5,956
5,876
5,899
6,476
6,212
6,114
6,021
6,973
7,470
8,288
8,020
58,809
58,461
58,406
57,955
57,844
57,462
57,076
56,807
56,80757,07657,46257,84457,95558,40658,46158,8098,0208,2887,4706,9736,0216,1146,2126,4765,8995,8765,9563,6283,5273,6753,5642,4792,6602,5292,2101,2061,000753732585600000
       Property Plant Equipment 
547
0
0
600
500
647
668
915
1,120
2,084
2,403
2,534
2,353
3,354
3,465
3,317
3,324
5,652
5,572
5,595
6,172
5,908
5,810
5,717
6,639
7,043
7,864
7,626
8,030
7,682
7,629
7,178
7,067
6,685
6,299
6,030
6,0306,2996,6857,0677,1787,6297,6828,0307,6267,8647,0436,6395,7175,8105,9086,1725,5955,5725,6523,3243,3173,4653,3542,3532,5342,4032,0841,12091566864750060000547
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
126
220
0
0
0
304
304
304
304
304
304
304
0
334
363
363
363
363
361
361
361
361
361
361
3613613613613613613633633633633340304304304304304304304000220126000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
233,243
0
0
0
0
50,416
0
50,416
50,416
50,416
50,416
50,416
50,416
50,41650,41650,41650,41650,41650,416050,4160000233,24300000000000000000000000
       Long-term Assets Other 
0
0
0
-100
85
-32
47
0
-6
-10
-29
-60
21
-64
25
0
0
2,082
5,876
5,899
6,476
6,212
0
304
334
93
61
31
363
50,416
0
0
361
-57,101
-56,715
-56,446
-56,446-56,715-57,1013610050,41636331619333430406,2126,4765,8995,8762,0820025-6421-60-29-10-6047-3285-100000
> Total Liabilities 
6,874
0
0
7,000
8,888
8,866
12,740
14,474
13,720
11,545
10,396
12,769
15,174
14,186
17,163
16,748
18,933
71,038
22,932
22,966
26,808
22,631
22,396
23,367
23,262
20,543
21,808
24,175
29,464
21,388
13,974
15,503
16,947
16,215
16,900
17,322
17,32216,90016,21516,94715,50313,97421,38829,46424,17521,80820,54323,26223,36722,39622,63126,80822,96622,93271,03818,93316,74817,16314,18615,17412,76910,39611,54513,72014,47412,7408,8668,8887,000006,874
   > Total Current Liabilities 
4,448
0
0
3,700
6,101
5,875
9,544
11,012
9,922
7,657
5,962
8,226
9,754
8,578
11,281
10,681
13,082
60,710
13,260
14,012
17,510
13,252
12,947
13,847
14,018
11,125
11,847
14,223
20,026
11,911
11,924
13,600
11,481
10,755
11,153
11,710
11,71011,15310,75511,48113,60011,92411,91120,02614,22311,84711,12514,01813,84712,94713,25217,51014,01213,26060,71013,08210,68111,2818,5789,7548,2265,9627,6579,92211,0129,5445,8756,1013,700004,448
       Short-term Debt 
0
0
0
0
0
0
4,719
6,768
0
0
386
392
395
455
0
0
332
47,535
749
760
1,094
759
759
751
443
441
571
577
570
573
577
581
548
551
553
555
5555535515485815775735705775714414437517597591,09476074947,53533200455395392386006,7684,719000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
386
392
395
455
841
0
358
47,119
329
334
652
324
321
441
0
0
0
0
0
0
0
0
0
0
0
0
00000000000044132132465233432947,11935808414553953923860000000000
       Accounts payable 
1,595
0
0
900
1,719
994
2,625
2,832
4,035
2,641
954
1,361
1,092
1,182
2,015
515
1,979
829
156
0
142
760
1,442
1,020
2,184
370
317
215
2,003
501
337
1,519
929
1,136
1,352
1,479
1,4791,3521,1369291,5193375012,0032153173702,1841,0201,44276014201568291,9795152,0151,1821,0921,3619542,6414,0352,8322,6259941,719900001,595
       Other Current Liabilities 
2,853
0
0
2,800
4,337
3,728
4,825
6,874
5,366
4,888
4,667
6,825
8,307
7,355
8,798
10,124
20,840
8,800
16,828
8,551
23,594
9,281
18,678
21,992
22,170
19,468
21,222
26,616
33,472
21,142
21,170
10,976
9,417
8,653
8,818
9,338
9,3388,8188,6539,41710,97621,17021,14233,47226,61621,22219,46822,17021,99218,6789,28123,5948,55116,8288,80020,84010,1248,7987,3558,3076,8254,6674,8885,3666,8744,8253,7284,3372,800002,853
   > Long-term Liabilities 
0
0
0
3,300
2,787
2,991
3,196
3,462
3,798
3,888
4,434
4,543
5,420
5,608
5,882
6,067
5,851
10,328
9,672
8,954
9,298
9,379
9,449
9,520
9,244
9,418
9,961
9,952
9,438
9,477
2,050
1,903
5,466
5,460
5,747
5,612
5,6125,7475,4605,4661,9032,0509,4779,4389,9529,9619,4189,2449,5209,4499,3799,2988,9549,67210,3285,8516,0675,8825,6085,4204,5434,4343,8883,7983,4623,1962,9912,7873,300000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
602
197
1,891
1,815
1,764
1,813
1,713
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,7131,8131,7641,8151,891197602000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-4,719
-6,768
0
0
-386
-392
-395
-455
0
0
-332
-45,453
1,230
1,133
1,161
1,389
1,281
1,050
1,780
1,706
2,126
1,992
2,340
2,196
2,050
1,903
2,253
2,115
1,976
1,838
1,8381,9762,1152,2531,9032,0502,1962,3401,9922,1261,7061,7801,0501,2811,3891,1611,1331,230-45,453-33200-455-395-392-38600-6,768-4,719000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,666
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001,66600000000000000000
> Total Stockholder Equity
23,623
0
0
48,200
71,043
64,679
90,542
146,209
142,380
133,054
120,892
112,672
116,839
105,828
95,393
191,976
177,623
241,854
273,290
292,383
272,442
265,601
250,862
233,243
215,478
207,416
189,282
179,221
231,979
214,131
202,812
190,054
168,991
152,935
139,328
125,664
125,664139,328152,935168,991190,054202,812214,131231,979179,221189,282207,416215,478233,243250,862265,601272,442292,383273,290241,854177,623191,97695,393105,828116,839112,672120,892133,054142,380146,20990,54264,67971,04348,2000023,623
   Common Stock
174
0
0
900
928
928
988
1,126
1,135
1,139
1,142
1,143
1,147
1,147
1,149
1,351
1,351
1,361
1,436
1,436
1,437
1,437
1,438
1,539
1,538
1,539
1,539
1,589
1,794
1,795
1,796
1,797
1,797
1,797
1,800
1,802
1,8021,8001,7971,7971,7971,7961,7951,7941,5891,5391,5391,5381,5391,4381,4371,4371,4361,4361,3611,3511,3511,1491,1471,1471,1431,1421,1391,1351,12698892892890000174
   Retained Earnings Total Equity000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-1,900
0
0
0
-2,200
-2,200
0
0
0
0
0
0
0
-3,836
-3,958
-4,165
-4,528
-4,896
-5,262
0
-5,717
-6,148
-6,623
0
0
0
49
72
10
2
-6
5
5-62107249000-6,623-6,148-5,7170-5,262-4,896-4,528-4,165-3,958-3,8360000000-2,200-2,200000-1,9000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
302,985
315,232
298,259
346,024
346,479
346,526
346,568
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000346,568346,526346,479346,024298,259315,232302,985000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
83,100
110,496
110,453
123,379
187,995
188,166
188,191
188,207
188,215
188,299
188,357
188,407
298,077
298,149
298,259
346,024
346,479
346,526
346,568
346,634
346,742
346,790
354,651
354,814
359,297
431,127
431,129
431,136
431,179
431,199
431,241
433,589
434,345
434,345433,589431,241431,199431,179431,136431,129431,127359,297354,814354,651346,790346,742346,634346,568346,526346,479346,024298,259298,149298,077188,407188,357188,299188,215188,207188,191188,166187,995123,379110,453110,49683,100000



Balance Sheet

Currency in CHF. All numbers in thousands.




Cash Flow

Currency in CHF. All numbers in thousands.




Income Statement

Currency in CHF. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1
Cost of Revenue--
Gross Profit-1
 
Operating Income (+$)
Gross Profit-
Operating Expense-68,781
Operating Income-68,780-68,781
 
Operating Expense (+$)
Research Development55,098
Selling General Administrative9,006
Selling And Marketing Expenses-
Operating Expense68,78164,104
 
Net Interest Income (+$)
Interest Income811
Interest Expense-149
Other Finance Cost-0
Net Interest Income662
 
Pretax Income (+$)
Operating Income-68,780
Net Interest Income662
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-68,227-68,780
EBIT - interestExpense = -149
-68,238
-68,089
Interest Expense149
Earnings Before Interest and Taxes (EBIT)--68,078
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-68,227
Tax Provision-11
Net Income From Continuing Ops-68,238-68,238
Net Income-68,238
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--662
 

Technical Analysis of AC Immune Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of AC Immune Ltd. The general trend of AC Immune Ltd is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine AC Immune Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of AC Immune Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.0601 < 5.14.

The bearish price targets are: 2.55 > 2.4645 > 2.3.

Tweet this
AC Immune Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of AC Immune Ltd. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I